Hakemisto 
 Edellinen 
 Seuraava 
 Koko teksti 
Menettely : 2018/2185(DEC)
Elinkaari istunnossa
Asiakirjan elinkaari : A8-0135/2019

Käsiteltäväksi jätetyt tekstit :

A8-0135/2019

Keskustelut :

PV 26/03/2019 - 12
CRE 26/03/2019 - 12

Äänestykset :

PV 26/03/2019 - 13.30
Äänestysselitykset

Hyväksytyt tekstit :

P8_TA(2019)0271

Puheenvuorot
Keskiviikko 27. maaliskuuta 2019 - Strasbourg Lopullinen versio

11.2. Vastuuvapaus 2017: Euroopan lääkevirasto (EMA) (A8-0135/2019 - Petri Sarvamaa)
Puheenvuorot videotiedostoina
 

Dichiarazioni di voto orali

 
  
MPphoto
 

  Alex Mayer (S&D). – Mr President, the GBP 500 million bill because the European Medicines Agency (EMA) could not get out of the 25—year lease on a building in Canary Wharf is deeply regrettable. What a waste. And, to my mind, what a waste to lose highly skilled jobs and research capacity from Britain. The EMA is a jewel in the crown, precisely because it attracts businesses and experts. Over the past two decades, it has been invaluable, simplifying and streamlining medicines regulation, allowing companies to get a medicine authorised in every EU country in one go. Alas for Britain, no more.

A medicines manufacturer in my constituency has already set up a new parallel testing facility within the EU to enable it to sell into European Union countries in the future. More cost, meaning less investment in research and development, and for Britain more delays in getting medicines and a rising bill for medicines, and so less money for our NHS – the opposite of what people thought that they were voting for.

 
Päivitetty viimeksi: 28. kesäkuuta 2019Oikeudellinen huomautus